We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Investors Should Stay Neutral on Community Health Stock Now
Read MoreHide Full Article
Key Takeaways
Community Health added surgery centers and expanded behavioral health and cardiac care services.
CYH raised cash balance to $712M and redeemed $223M in senior secured notes during the quarter.
CYH reported a negative operating cash flow of $297 million in first-quarter 2026.
Community Health Systems (CYH - Free Report) is benefiting from stabilizing operations and a favorable mix shift toward higher-acuity services, including cardiology and behavioral health. Ongoing divestitures are also aiding operational streamlining and debt reduction.
Community Health currently has a market capitalization of approximately $397.4 million. Based on the short-term price targets of seven analysts, the stock carries a mean target price of $3.31, implying an upside of 17.4% from the last closing price of $2.82. CYH currently carries a Zacks Rank #3 (Hold).
Valuation of CYH
Its forward price-to-sales (P/S) ratio of 0.03X is significantly below the industry average of 0.62X, suggesting an attractive valuation relative to peers. The stock has declined 2.7% over the past six months, outperforming the broader industry’s 9.3% decline during the same period.
Zacks Estimates for CYH
The Zacks Consensus Estimate for revenues is pegged at $11.6 billion for 2026 and $11.7 billion for 2027. The consensus estimate calls for a loss of 58 cents per share in 2026, narrowing to a loss of 17 cents in 2027. It has witnessed one upward earnings estimate revision over the past month against two downward revisions, for 2026.
CYH’s earnings beat the Zacks Consensus Estimate in two of the trailing four quarters and missed in the other two, delivering an average surprise of 57.6%.
Community Health Systems, Inc. Price, Consensus and EPS Surprise
Community Health is benefiting from targeted expansion efforts and operational improvements across its existing markets. The company continues to invest in de novo facilities and higher-acuity service lines, including behavioral health, cardiac care and women’s services, which support stronger margins and improved market positioning. In the first half of 2026, CYH acquired a majority interest in South Anchorage Surgery Center and opened two de novo ambulatory surgery centers in Alabama. By expanding within established markets, the company is improving referral alignment and operating leverage.
CYH is also benefiting from portfolio optimization and cost-control initiatives. The company has continued divesting non-core assets to focus on higher-performing markets and strengthen its balance sheet. Leverage improved from 7.4x at the end of 2024 to 6.5x in the first quarter of 2026. Meanwhile, technology-driven productivity initiatives across revenue cycle and supply-chain operations helped lower costs. These moves have reduced total operating expenses by 6.6% year over year in the first quarter.
Community Health exited the first quarter with cash and cash equivalents of $712 million, up from $260 million at 2025-end, while long-term debt declined to $10.13 billion from $10.38 billion. The company also redeemed approximately $223 million of senior secured notes during the quarter. The improved liquidity position and lower debt burden are expected to improve financial flexibility and support long-term profitability.
CHY: Key Risks
There are a few factors that investors should keep an eye on.
Community Health continues to face financial and operational pressures. Net cash used in operating activities was $297 million in the first quarter of 2026 compared to operating cash flow of $120 million in the prior-year quarter, indicating weaker cash generation from core operations.
It’s return on invested capital (ROIC) of 8.71% also trails the industry average of 9.24%, suggesting relatively weaker capital efficiency compared with peers.
The Zacks Consensus Estimate for Indivior Pharmaceuticals’ 2026 earnings is pegged at $3.35 per share, indicating a 34% year-over-year improvement. INDV beat earnings estimates in each of the trailing four quarters, with the average surprise being 65.4%. The consensus estimate for 2026 revenues is pinned at $1.3 billion, implying 1.5% year-over-year growth.
The Zacks Consensus Estimate for BrightSpring Health’s 2026 earnings is pegged at $1.64 per share, which has witnessed five upward revisions in the past 30 days, with no movement in the opposite direction. BTSG beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 14.6%. The consensus estimate for 2026 revenues is pinned at $15.1 billion, implying 16.6% year-over-year growth.
The Zacks Consensus Estimate for Centene’s 2026 earnings is pegged at $3.47 per share, which has witnessed nine upward revisions in the past 30 days, with no movement in the opposite direction. CNC beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 74.9%. The consensus estimate for 2026 revenues is pinned at $190.8 billion.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Why Investors Should Stay Neutral on Community Health Stock Now
Key Takeaways
Community Health Systems (CYH - Free Report) is benefiting from stabilizing operations and a favorable mix shift toward higher-acuity services, including cardiology and behavioral health. Ongoing divestitures are also aiding operational streamlining and debt reduction.
Community Health currently has a market capitalization of approximately $397.4 million. Based on the short-term price targets of seven analysts, the stock carries a mean target price of $3.31, implying an upside of 17.4% from the last closing price of $2.82. CYH currently carries a Zacks Rank #3 (Hold).
Valuation of CYH
Its forward price-to-sales (P/S) ratio of 0.03X is significantly below the industry average of 0.62X, suggesting an attractive valuation relative to peers. The stock has declined 2.7% over the past six months, outperforming the broader industry’s 9.3% decline during the same period.
Zacks Estimates for CYH
The Zacks Consensus Estimate for revenues is pegged at $11.6 billion for 2026 and $11.7 billion for 2027. The consensus estimate calls for a loss of 58 cents per share in 2026, narrowing to a loss of 17 cents in 2027. It has witnessed one upward earnings estimate revision over the past month against two downward revisions, for 2026.
CYH’s earnings beat the Zacks Consensus Estimate in two of the trailing four quarters and missed in the other two, delivering an average surprise of 57.6%.
Community Health Systems, Inc. Price, Consensus and EPS Surprise
Community Health Systems, Inc. price-consensus-eps-surprise-chart | Community Health Systems, Inc. Quote
Growth Drivers
Community Health is benefiting from targeted expansion efforts and operational improvements across its existing markets. The company continues to invest in de novo facilities and higher-acuity service lines, including behavioral health, cardiac care and women’s services, which support stronger margins and improved market positioning. In the first half of 2026, CYH acquired a majority interest in South Anchorage Surgery Center and opened two de novo ambulatory surgery centers in Alabama. By expanding within established markets, the company is improving referral alignment and operating leverage.
CYH is also benefiting from portfolio optimization and cost-control initiatives. The company has continued divesting non-core assets to focus on higher-performing markets and strengthen its balance sheet. Leverage improved from 7.4x at the end of 2024 to 6.5x in the first quarter of 2026. Meanwhile, technology-driven productivity initiatives across revenue cycle and supply-chain operations helped lower costs. These moves have reduced total operating expenses by 6.6% year over year in the first quarter.
Community Health exited the first quarter with cash and cash equivalents of $712 million, up from $260 million at 2025-end, while long-term debt declined to $10.13 billion from $10.38 billion. The company also redeemed approximately $223 million of senior secured notes during the quarter. The improved liquidity position and lower debt burden are expected to improve financial flexibility and support long-term profitability.
CHY: Key Risks
There are a few factors that investors should keep an eye on.
Community Health continues to face financial and operational pressures. Net cash used in operating activities was $297 million in the first quarter of 2026 compared to operating cash flow of $120 million in the prior-year quarter, indicating weaker cash generation from core operations.
It’s return on invested capital (ROIC) of 8.71% also trails the industry average of 9.24%, suggesting relatively weaker capital efficiency compared with peers.
Top-Ranked Players
Some better-ranked stocks in the broader Medical space areIndivior Pharmaceuticals, Inc. (INDV - Free Report) , BrightSpring Health Services, Inc. (BTSG - Free Report) and Centene Corporation (CNC - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Indivior Pharmaceuticals’ 2026 earnings is pegged at $3.35 per share, indicating a 34% year-over-year improvement. INDV beat earnings estimates in each of the trailing four quarters, with the average surprise being 65.4%. The consensus estimate for 2026 revenues is pinned at $1.3 billion, implying 1.5% year-over-year growth.
The Zacks Consensus Estimate for BrightSpring Health’s 2026 earnings is pegged at $1.64 per share, which has witnessed five upward revisions in the past 30 days, with no movement in the opposite direction. BTSG beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 14.6%. The consensus estimate for 2026 revenues is pinned at $15.1 billion, implying 16.6% year-over-year growth.
The Zacks Consensus Estimate for Centene’s 2026 earnings is pegged at $3.47 per share, which has witnessed nine upward revisions in the past 30 days, with no movement in the opposite direction. CNC beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 74.9%. The consensus estimate for 2026 revenues is pinned at $190.8 billion.